Corporate Corruption Media Articles

Excerpts of Key Corporate Corruption Media Articles in Major Media

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Across the pharmaceutical and medical industries, senior executives and board members are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March, according to figures compiled for The New York Times. The sudden windfalls highlight the powerful financial incentives for company officials to generate positive headlines in the race for coronavirus vaccines and treatments, even if the drugs might never pan out. Some officials at the Department of Health and Human Services have grown concerned about whether companies are trying to inflate their stock prices by exaggerating their roles in Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. In some cases, company insiders ... appear to be pouncing on opportunities to cash out while their stock prices are sky high. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. "It is inappropriate for drug company executives to cash in on a crisis," said Ben Wakana, executive director of Patients for Affordable Drugs. "Every day, Americans wake up and make sacrifices during this pandemic. Drug companies see this as a payday."

Note: For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.

Big corporations accused of driving environmental and health inequalities in black and brown communities through toxic and climate-changing pollution are also funding powerful police groups in major US cities, according to a new investigation. Some of America’s largest oil and gas companies, private utilities, and financial institutions that bankroll fossil fuels also back police foundations – opaque private entities that raise money to pay for training, weapons, equipment, and surveillance technology for departments across the US. The investigation by the Public Accountability Initiative, a nonprofit corporate and government accountability research institute ... details how police foundations in cities such as Seattle, Chicago, Washington, New Orleans and Salt Lake City are partially funded by household names such as Chevron, Shell and Wells Fargo. Police foundations are industry groups that provide substantial funds to local departments, yet, as nonprofits, avoid much public scrutiny. The investigation details how firms linked to fossil fuels also sponsor events and galas that celebrate the police, while some have senior staff serving as directors of police foundations. The report portrays the fossil fuel industry as a common enemy in the struggle for racial and environmental justice. “Many powerful companies that drive environmental injustice are also backers of the same police departments that tyrannize the very communities these corporate actors pollute,” it states.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in policing and in the corporate world from reliable major media sources.

On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.

Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.

Federal charging documents unsealed Tuesday describe how the company, FirstEnergy, spent $60 million to get House Speaker Larry Householder and his favored candidates elected, securing in return a $1.3 billion bailout, paid for by Ohio ratepayers. Householder and Jeff Longstreth, a top aide ... set up Generation Now, a secretive political nonprofit that could raise and spend unlimited amounts of money. “Having secured Householder’s power as Speaker, the Enterprise transitioned quickly to fulfilling its end of the corrupt bargain with Company A — Passing nuclear bailout legislation,” the complaint reads. After Gov. Mike DeWine signed the bill ... opponents, allied with natural-gas and environmental interests in the state, got to work trying to repeal it. They cleared an initial hurdle, collecting 1,000 valid signatures from voters. They had until Oct. 21 to gather hundreds of thousands more signatures. FirstEnergy and FirstEnergy Solutions sent $38 million to Generation Now. The campaign spent millions on mailers and ads discouraging Ohioans from signing the petitions. It also hired petition firms to prevent them from working for the repeal side. “For example,” the complaint reads,” in a meeting on July 24, 2019, which was recorded, [lobbyist Neil] Clark stated that he wired about $450,000 today hiring signature collections people to not work.” Some of the petitioners worked as “blockers,” disrupting the other side’s signature gathering efforts by following them around and making possible signers uncomfortable.

Note: For more along these lines, see concise summaries of deeply revealing news articles on government corruption and nuclear power from reliable major media sources.

Moderna CEO StÄ‚©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

It's a fairly ordinary evening on TikTok, the video-sharing app. Things do not seem so different on Douyin, the Chinese version of TikTok, where a live streaming boom has minted new social media millionaires. Behind the scenes, however, Chinese streamers are subject to an elaborate regime of automated surveillance and censorship. One system can use facial recognition to scan live streamers' broadcasts and guess their age. Another checks whether users' faces match their state ID cards. Another system assigns streamers, who are expected to uphold "public order and good customs", a "safety rating", similar to a "credit score". If the score dips below a certain level, they are punished automatically. Meanwhile, speech and text recognition is used to ferret out sins such as "feudal superstition" [and] defamation of the Communist Party. These methods are laid bare in a little-known document from TikTok and Douyin's parent company, ByteDance, and unearthed by New York City journalist Izzy Niu, which explains how the apps have adapted China's strict internet censorship laws to the unprecedented speed and chaos of live streaming. The document raises difficult questions for TikTok, which faces privacy probes in the US and UK and has already been banned in India. Some of these methods are common in the West, too. Both Facebook and YouTube use AI to police their services, and have massively expanded their censorship during the pandemic.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption and the disappearance of privacy from reliable major media sources.

OxyContin maker Purdue Pharma should not be able to make any more political contributions without a judge’s permission, lawyers for its creditors said in a court filing. The issue came up this week after it was reported that the company, which has a long history of influencing policymakers, made contributions to national associations representing state attorneys general and governors. The money was sent after Purdue entered bankruptcy protection last year in an effort to settle thousands of lawsuits accusing it of helping spark an opioid addiction and overdose epidemic that has contributed to more than 400,000 deaths in the U.S.. State attorneys general are among those trying to negotiate a nationwide settlement. The committee of creditors that asked for recipients to return the money to Purdue said the contributions represent a conflict. “The Political Contributions — $185,000 in donations to associations whose members include the very public servants with whom the Debtors are attempting to negotiate a consensual resolution of these cases — are precisely the sort of transaction that demand close scrutiny,” they said in a filing. In 2016, an investigation by The Associated Press and the Center for Public Integrity found that Purdue and other companies in the opioid industry, along with the advocacy groups largely funded by the industry, spent more than $880 million from 2006 through 2015 to influence state and local governments. Those efforts helped fight off restrictions on drug prescriptions.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Scientists have devised a way to use the antibody-rich blood plasma of COVID-19 survivors for an upper-arm injection that they say could inoculate people against the virus for months. Using technology that's been proven effective in preventing other diseases such as hepatitis A, the injections would be administered to high-risk healthcare workers, nursing home patients, or even at public drive-through sites. But the idea exists only on paper. Federal officials have twice rejected requests to discuss the proposal, and pharmaceutical companies — even acknowledging the likely efficacy of the plan — have declined to design or manufacture the shots. The antibodies in plasma can be concentrated and delivered to patients through a type of drug called immune globulin, or Ig, which can be given through either an IV drip or a shot. Yet for the coronavirus, manufacturers are only developing an intravenous solution of Ig. Intravenous plasma products are traditionally the main economic driver for the industry. The money-making antibodies are also far more diluted in intravenous drugs than in injectable ones, which boosts profit margins. “They charge a fortune off of intravenous drugs in the hospital. They don't want to devote the manufacturing plant to something that won't make oodles of money,” said one infectious disease expert. Researchers also said industry executives have little incentive to produce the immunity shots for the coronavirus, given the possibility that a longer-lasting vaccine could replace it within a year.

Note: For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.

Ties between Silicon Valley and the Pentagon are deeper than previously known, according to thousands of previously unreported subcontracts published Wednesday. The subcontracts were obtained through open records requests by accountability nonprofit Tech Inquiry. They show that tech giants including Google, Amazon, and Microsoft have secured more than 5,000 agreements with agencies including the Department of Defense, Immigrations and Customs Enforcement, the Drug Enforcement Agency, and the FBI. Tech workers in recent years have pressured their employers to drop contracts with law enforcement and the military. Google workers revolted in 2018 after Gizmodo revealed that Google was building artificial intelligence for drone targeting through a subcontract with the Pentagon after some employees quit in protest, Google agreed not to renew the contract. Employees at Amazon and Microsoft have petitioned both companies to drop their contracts with ICE and the military. Neither company has. The newly-surfaced subcontracts ... show that the companies' connections to the Pentagon run deeper than many employees were previously aware. Tech Inquiry's research was led by Jack Poulson, a former Google researcher. "Often the high-level contract description between tech companies and the military looks very vanilla," Poulson [said]. "But only when you look at the details ... do you see the workings of how the customization from a tech company would actually be involved."

Note: For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the corporate world from reliable major media sources.

When Oswald Bilotta landed his dream job as a sales representative for Novartis Pharmaceuticals in 1999, he thought he'd be doing good. He had no idea that just over a decade later, he'd be part of a vast federal investigation into kickbacks at Novartis and that he'd be paying cash bribes to doctors while wearing a wire for prosecutors. On July 1, Ozzie Bilotta's years long effort to blow the whistle at Novartis paid off. The Justice Department announced a $678 million settlement with the company over improper inducements it made to doctors to prescribe 10 of the company's drugs, including the anti-hypertension drug Lotrel. The deal represents the biggest whistleblower settlement under the federal anti-kickback law, Bilotta's lawyer said. Bilotta ... could receive a pretax sum of $75 million through the settlement. In the settlement, Novartis admitted to "certain conduct" alleged by the government and will sharply curtail practices exposed by Bilotta that gave doctors incentives to prescribe its drugs. Novartis derived at least $40 million as a result of the conduct, money that was paid by federal health care programs, the government said. "For more than a decade, Novartis spent hundreds of millions of dollars on so-called speaker programs, including speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis's drugs," said Audrey Strauss, the acting U.S. attorney for southern New York, whose office prosecuted the case.

Note: For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption from reliable major media sources.

Deutsche Bank (DBK.DE) has agreed to pay $150m (Ł119m) over compliance failings in part linked to dealings with Jeffrey Epstein. New York’s Department of Financial Services said in a statement on Tuesday it had imposed the penalty on Deutsche Bank’s New York branch for “significant compliance failures in connection with the Bank’s relationship with Jeffrey Epstein,” the accused child sex trafficker who died in police custody last year. The penalty also covers anti-money laundering failings linked to Danske Bank Estonia and Middle Eastern bank FBME. Epstein, who is believed to have been a billionaire, became a client of Deutsche Bank’s in 2013, five years after he pleaded guilty to procuring for prostitution a girl below age 18 in Florida. Despite coverage of the settlement and subsequent allegations against Epstein, investigators found Deutsche Bank failed to properly monitor his account. “Hundreds of transactions totalling millions of dollars” that raised red flags were missed, the New York Department of Financial Services said. These included payments to Epstein’s alleged co-conspirators, settlement payments with victims totalling $7m, payments to Russian models, payments for women’s school tuition and expenses, and payments to “numerous women with Eastern European surnames” that were “consistent with public allegations of prior wrongdoing.” Repeated “suspicious” cash withdrawals by Epstein — totally over $800,000 over four years — also failed to raise concerns.

Note: 60 Minutes Australia has produced an excellent segment on Jeffrey Epstein and his recently arrested sidekick Ghislaine Maxwell. How did Epstein get away with sexually abusing hundreds of teenage girls for decades? The government and multiple police departments knew what was happening, yet key officials in high positions of power protected him. For more along these lines, see concise summaries of deeply revealing news articles on Jeffrey Epstein and financial industry corruption from reliable major media sources.

Forty lobbyists with ties to President Donald Trump helped clients secure more than $10 billion in federal coronavirus aid. The lobbyists identified Monday by the watchdog group Public Citizen either worked in the Trump executive branch, served on his campaign, were part of the committee that raised money for inaugural festivities or were part of his presidential transition. Many are donors to Trump’s campaigns. Trump pledged to clamp down on Washington's influence peddling with a “drain the swamp” campaign mantra. But during his administration, the lobbying industry has flourished, a trend that intensified once Congress passed more than $3.6 trillion in coronavirus stimulus. While the money is intended as a lifeline to a nation whose economy has been upended by the pandemic, it also jump-started a familiar lobbying bonanza. Shortly after Trump took office, he issued an executive order prohibiting former administration officials from lobbying the agency or office where they were formerly employed, for a period of five years. Another section of the order forbids lobbying the administration by former political appointees for the remainder of Trump's time in office. Yet five lobbyists who are former administration officials have potentially done just that during the coronavirus lobbying boom. Public Citizen's Craig Holman, who himself is a registered lobbyist, said the group intends to file ethics complaints with the White House. But he's not optimistic that they will lead to anything.

Note: For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors. The price was swiftly criticized; a consumer group called it “an outrage” because of the amount taxpayers invested toward the drug's development. In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug; two countries are doing that for around $600 per treatment course. The drug, given through an IV, interferes with the coronavirus’s ability to copy its genetic material. In a U.S. government-led study, remdesivir shortened recovery time by 31% — 11 days on average versus 15 days for those given just usual care. Peter Maybarduk, a lawyer at the consumer group Public Citizen, called the price “an outrage.” “Remdesivir should be in the public domain” because the drug received at least $70 million in public funding toward its development, he said. “The price puts to rest any notion that drug companies will ‘do the right thing’ because it is a pandemic,” Dr. Peter Bach, a health policy expert ... said. “The price might have been fine if the company had demonstrated that the treatment saved lives. It didn’t.”

Note: The March coronavirus package passed in the U.S. "not only omitted language that would have limited drug makers’ intellectual property rights, it specifically prohibited the federal government from taking any action if it has concerns that the treatments or vaccines developed with public funds are priced too high." While many suffer economically from the virus, big Pharma is raking in big bucks. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and the coronavirus from reliable major media sources.

Bayer will pay more than $10 billion to resolve thousands of lawsuits regarding claims that its Roundup herbicide causes cancer, the company announced. Monsanto, bought by Bayer in 2018, lost a lawsuit that same year brought by a school groundskeeper who claimed its weedkiller had caused his non-Hodgkin's lymphoma. Since then, thousands of U.S. lawsuits have been filed against the company. The settlement, however, does not contain an admission of wrongdoing or liability. Bayer will pay $8.8 billion to $9.6 billion to settle existing lawsuits and then another $1.25 billion that will cover any potential litigation in the future. Lawsuits allege that Monsanto ignored warnings that its herbicide contained potentially cancer causing chemicals, then concealed the threat to consumers. A jury awarded California groundskeeper Dewayne Johnson nearly $290 million in damages in August 2018 after they found Monsanto failed to warn Johnson and other consumers about the risks posed by its weed-killing products. A judge upheld the decision upon appeal, but lowered the damages to $78 million due to what she considered an overreach in punitive damages decided by the jury. And last year, a California jury awarded a husband and wife more than $2 billion in damages in a suit that claimed Roundup caused their illness. German pharmaceuticals and chemical giant Bayer bought Monsanto in 2018 just months before Johnson won his suit against the company. Bayer eliminated the Monsanto name, but maintained the brands.

Note: The negative health impacts of Roundup are well known. Yet the EPA continues to use industry studies to declare Roundup safe while ignoring independent scientists. For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.

Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products. By the time the selling was disclosed to the public via securities filings, Moderna's stock price had crashed back to Earth. The timing of the transactions - coupled with concerns from some medical experts that Moderna overstated the significance of its Phase 1 vaccine trial - should be investigated by authorities. Thomas Gorman, [a] former SEC official, said the agency should "absolutely" be investigating the situation at Moderna.

Note: Why didn't the media report that the Moderna vaccine trial had a 20% serious injury rate in the high dose group? Learn about this and much more in this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject. To make progress, Gilead needed help from U.S. taxpayers. Lots of help. Three federal health agencies were deeply involved in remdesivir’s development every step of the way, providing tens of millions of dollars of government research support. Federal agencies have not asserted patent rights to Gilead’s drug. That means Gilead will have few constraints other than political pressure when it sets a price. “Without direct public investment and tax subsidies, this drug would apparently have remained in the scrapheap of unsuccessful drugs,” Rep. Lloyd Doggett (D-Tex.) ... said earlier this month. Doggett and Rep. Rosa L. DeLauro (D-Conn.) have asked Health and Human Services Secretary Alex Azar for a detailed financial accounting of federal support for remdesivir’s discovery and development. Watchdog groups ... have documented the large taxpayer-funded contributions toward the drug. Public Citizen estimates public investment at a minimum of $70 million. An independent organization that measures the cost-effectiveness of drugs said Gilead could be justified in charging up to $4,500 for a 10-day course of treatment for a single coronavirus patient. But advocates, citing a study by academic researchers on what it costs to make the drug, have said Gilead could break even by charging $1 per dose.

Note: According to this CNBC article Gilead is charging from $2,000 to $3,120 per patient despite huge subsidies. Gilead is the same company which developed Tamiflu and licensed it to Roche. Aggressive sales of Tamiflu to governments around the world brought profits of over $1 billion yet almost none of the doses sold were ever used, as described in this Reuters article. The study that is being used to tout Remdesivir was conducted by none other than Gilead. Could there be conflict of interest here? For more, see summaries of revealing news articles on big Pharma corruption.

When the Federal Reserve needed Wall Street's help with its pandemic rescue mission, it went straight to Larry Fink. The BlackRock cofounder, chairman, and chief executive officer has become one of the industry's most important government whisperers. The company's new assignment is a much bigger version of one it took on after the 2008 financial crisis, when the Federal Reserve enlisted it to dispose of toxic mortgage securities. This time it will help the Fed prop up the entire corporate bond market by purchasing, on the central bank's behalf, what could become a $750 billion portfolio of debt. One part of the Fed's plan is to buy bond exchange-traded funds. BlackRock itself runs ETFs under the iShares brand, and could end up buying funds it manages. "BlackRock is acting as a fiduciary to the Federal Reserve Bank of New York," says a spokesman for the company. "As such, BlackRock will execute this mandate at the sole discretion of the bank." The arrangement is bringing new attention to the company's scale and ubiquity. "It's impossible to think of BlackRock without thinking of them as a fourth branch of government," says William Birdthistle, a professor at the Chicago-Kent College of Law. BlackRock's growth raises questions over how big and useful a company can become before its size poses a risk. And then there are the potential conflicts. One arm of BlackRock knows what the Fed is buying, while other parts of the business participating in credit markets could benefit from that knowledge.

Note: Watch an excellent documentary showing how BlackRock, Vanguard, and several other institutions are the largest shareholders in almost every major corporation you can think of. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the financial industry from reliable major media sources.

Big Tech companies are aggressively tamping down on COVID-19 “misinformation” — opinions and ideas contrary to official pronouncements. Dr. Knut M. Wittkowski, former head of biostatistics, epidemiology and research design at Rockefeller University, says YouTube removed a video of him talking about the virus that had racked up more than 1.3 million views. Wittkowski, 65, is a ferocious critic of the nation’s current steps to fight the coronavirus. He has derided social distancing, saying it only prolongs the virus’ existence, and has attacked the current lockdown as mostly unnecessary. Wittkowski, who holds two doctorates in computer science and medical biometry, believes the coronavirus should be allowed to create “herd immunity,” and that short of a vaccine, the pandemic will only end after it has sufficiently spread through the population. “I was just explaining what we had,” Wittkowski told The Post of the video, saying he had no idea why it was removed. “They don’t tell you. They just say it violates our community standards. There’s no explanation for what those standards are or what standards it violated.” In articles and interviews across the web, he has likened COVID-19 to a “bad flu.” That likely made him a target for YouTube. “Anything that goes against [World Health Organization] recommendations would be a violation of our policy,” CEO Susan Wojcicki told CNN.

Note: For more along these lines, see concise summaries of deeply revealing news articles on media corruption and the coronavirus from reliable major media sources.

During New York Gov. Andrew Cuomo’s daily coronavirus briefing on Wednesday, the somber grimace that has filled our screens for weeks was briefly replaced by something resembling a smile. The inspiration ... was a video visit from former Google CEO Eric Schmidt, who joined the governor’s briefing to announce that he will be heading up a blue-ribbon commission to reimagine New York state’s post-Covid reality, with an emphasis on permanently integrating technology into every aspect of civic life. Just one day earlier, Cuomo had announced a similar partnership with the Bill and Melinda Gates Foundation to develop “a smarter education system.” It has taken some time to gel, but something resembling a coherent Pandemic Shock Doctrine is beginning to emerge. Call it the “Screen New Deal.” Far more high-tech than anything we have seen during previous disasters, the future that is being rushed into being as the bodies still pile up treats our past weeks of physical isolation not as a painful necessity to save lives, but as a living laboratory for a permanent — and highly profitable — no-touch future. This is a future in which, for the privileged, almost everything is home delivered, either virtually via streaming and cloud technology, or physically via driverless vehicle or drone, then screen “shared” on a mediated platform. It’s a future in which our every move, our every word, our every relationship is trackable, traceable, and data-mineable by unprecedented collaborations between government and tech giants.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus pandemic and the disappearance of privacy from reliable major media sources.

The nursing home industry has been devastated by the coronavirus, with outbreaks killing thousands of elderly residents. But the health crisis presents operators with a potential financial upside. Patients with COVID-19 could be worth more than four times what homes are able to charge for long-term residents with relatively mild health issues. Some patient advocates and industry experts fear the premium pay available for coronavirus patients – and a simultaneous easing of regulations around transfers – could tempt some home operators to move out low-paying residents to bring in more lucrative COVID-19 patients, despite the obvious health risks to residents and staff. "There are probably some unscrupulous operators who would jump at this," said David Grabowski, a professor of healthcare policy at Harvard Medical School. A new Medicare reimbursement system that went into effect last fall pays nursing homes substantially more for new patients – including those released from a hospital – particularly for the first few weeks. Under those guidelines, COVID-19 patients can bring in upward of $800 per day. By contrast, facilities collect as little as $200 per day for long-term patients with dementia. Nursing homes have always had a financial incentive to attract the short-term patients ... Grabowski said. But the health risks for existing residents and staff are so high with COVID-19, Grabowski said, "I'd be a little suspicious of a low-quality nursing home that's jumping to the head of the line for this."

Note: Another excellent article presents more important questions on how this might skew death statistics for the coronavirus. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.

Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.